Fulvestrant 250mg Injection Franchise in Ahmedabad

Hormonal Therapy Injection Supplier in Bangalore

Fulvestrant Injection Distributor in Hyderabad

Breast Cancer Treatment Injection Franchise Opportunity in Jaipur

Oncology Injectable Stockist in Mumbai
Fulvestrant Injection Export & Manufacturing in Chandigarh

Home/Products /fulvestrant-250mg-injection

About the Product

Description


Fultrant 250 Injection contains Fulvestrant 250mg, a selective estrogen receptor degrader widely used for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. Its targeted mechanism helps slow disease progression by blocking estrogen’s effect on cancer cells.

Fulvestrant binds to estrogen receptors, promotes receptor degradation, and reduces tumor proliferation. The 250mg injectable formulation provides consistent plasma levels, ensuring reliable clinical efficacy for patients requiring long-term hormonal therapy in advanced breast cancer treatment protocols.

For hospitals, oncology centers, and pharmaceutical distributors, Fultrant 250 Injection is a high-demand oncology product, commonly used in cancer-care units, specialized breast cancer clinics, and multispecialty hospitals. Ongoing therapy and frequent dosing cycles drive continuous market demand.

Adding Fultrant 250 Injection to your oncology portfolio strengthens your hormonal therapy and cancer-care segment, enabling strong opportunities in institutional procurement, private hospital chains, government tenders, export consignments, and third-party manufacturing. Its clinical importance and steady prescription pattern make it a commercially valuable product for pharmaceutical distributors.

Some patients may experience nausea, injection site pain, fatigue, hot flashes, or headache. Rarely, liver enzyme abnormalities, thrombocytopenia, or allergic reactions may occur.

Fultrant 250 Injection is indicated for the treatment of hormone receptor-positive metastatic or advanced breast cancer in postmenopausal women. It helps slow tumor progression and manage disease in patients resistant to prior endocrine therapy.

Use strictly under medical supervision. Avoid in patients with hypersensitivity to Fulvestrant. Liver function should be monitored during therapy. Administer the injection as prescribed by a healthcare professional.

Store in a cool, dry place below 25°C, protected from light. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Fulvestrant 250mg Injection in the PCD pharma franchise market?

Fulvestrant 250mg Injection has strong demand in the oncology, women's healthcare, hospital care, and specialty healthcare segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on oncology and specialty injectable portfolios.

Why should medical distributors include Fulvestrant 250mg Injection in their product range?

Medical distributors and agencies can benefit from demand for specialized oncology treatments administered under strict medical supervision. Fulvestrant 250mg Injection is a hormonal therapy used in the management of certain hormone receptor-positive breast cancers Commonly prescribed for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer as recommended by oncologists and clinical treatment guidelines Works by blocking and degrading estrogen receptors, helping to slow the growth of hormone-sensitive cancer cells Injectable formulation enables administration in specialized oncology and hospital settings Requires administration and monitoring by qualified oncology professionals Frequently utilized in cancer hospitals, oncology centers, specialty clinics, and tertiary care institutions Widely prescribed by medical oncologists and cancer specialists This strengthens a comprehensive oncology and women's healthcare portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this product?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Fulvestrant 250mg Injection with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and medical agencies benefit from institutional demand, oncology market opportunities, hospital procurement requirements, reliable supply chain support, and attractive margins in the specialty injectable segment.

How can I become a distributor or franchise partner for this product?

Interested distributors, stockists, and wholesalers can partner with Cafoli LifeCare Pvt Ltd to access lucrative PCD pharma franchise opportunities across India. With exclusive monopoly rights, extensive promotional support, high-quality pharmaceutical products, attractive business margins, and dependable logistics support, Cafoli LifeCare Pvt Ltd helps franchise partners build a successful and profitable pharmaceutical business.